Voyager Therapeutics, Inc.
VYGR
$3.36
$0.010.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -19.67% | 3.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -19.67% | 3.11% | |||
| Cost of Revenue | -0.62% | -3.90% | |||
| Gross Profit | -4.30% | 5.56% | |||
| SG&A Expenses | 8.87% | 7.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.60% | -1.52% | |||
| Operating Income | -5.57% | 2.34% | |||
| Income Before Tax | -7.69% | 8.61% | |||
| Income Tax Expenses | -59.46% | -93.66% | |||
| Earnings from Continuing Operations | -7.61% | 10.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.61% | 10.05% | |||
| EBIT | -5.57% | 2.34% | |||
| EBITDA | -5.59% | 2.41% | |||
| EPS Basic | -7.04% | 10.64% | |||
| Normalized Basic EPS | -7.11% | 1.10% | |||
| EPS Diluted | -7.22% | 11.07% | |||
| Normalized Diluted EPS | -7.11% | 1.10% | |||
| Average Basic Shares Outstanding | 0.54% | 0.65% | |||
| Average Diluted Shares Outstanding | 0.54% | 0.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||